Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00378196
Other study ID # NA_00002686
Secondary ID
Status Completed
Phase Phase 1
First received September 18, 2006
Last updated November 12, 2012
Start date September 2006
Est. completion date December 2008

Study information

Verified date November 2012
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT. IPT is caused by swelling in the retina (the light sensitive tissue in the back of the eye) due to leaky blood vessels in this area. Swelling in the retina can lead to blurry vision.


Description:

This study is a randomized, interventional case series. A total of 10 patients, seen in the Retina Division of the Wilmer Eye Institute, will be enrolled. Subjects will be randomized to either 0.3 mg or 0.5 mg intravitreal injections of ranibizumab. Patients with IPT with macular edema documented on optical coherence tomography (OCT) but no choroidal neovascularization will be eligible for this study. Exclusion criteria will include other forms of retinopathy, active intraocular inflammation, history of poor vision due to conditions other than IPT in either eye, and known hypersensitivity to humanized monoclonal antibodies.

After obtaining informed consent, the patient will undergo baseline assessment including best-corrected Early Treatment for Diabetic Retinopathy Study (ETDRS) visual acuity, ocular examination, color fundus photography, fluorescein angiography, and OCT. If both eyes are eligible, the study participant and investigator will choose which eye to be considered the study eye. The study eye will be assigned at random to receive an intravitreal dose of ranibizumab (0.3 mg/0.05 ml or 0.5 mg/0.05 ml) at the baseline, 1 month, and 2 month visits. Further monthly injections are at the discretion of the examiner, and may be withheld if there is lack of continued improvement (defined as lack of improvement of at least 5 letters on an eye chart compared with 2 previous consecutive visits or lack of decrease of the retinal center point thickness of at least 50 microns compared with 2 previous consecutive visits) or complete success (defined as visual acuity of 20/20 or better or retinal center point thickness <225 microns).


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 2008
Est. primary completion date September 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects will be eligible if the following criteria are met:

1. Ability to provide written informed consent and comply with study assessments for the full duration of the study.

2. Age > 18 years

3. Diagnosis of bilateral IPT with macular edema documented on OCT and no evidence of choroidal neovascularization.

4. Best corrected visual acuity of better or equal to 20/200 in both eye

Exclusion Criteria:

- Subjects who meet any of the following criteria will be excluded from this study:

1. Known hypersensitivity to humanized monoclonal antibodies

2. History (within past 6 months) or evidence of severe cardiac disease (apparent in electrocardiogram abnormalities, clinical history of unstable angina, acute coronary syndrome, myocardial infarction, revascularization procedure within 6 months prior to baseline, atrial or ventricular tachyarrhythmias requiring ongoing treatment).

3. History of stroke within 6 months of study entry.

4. Current acute ocular or periocular infection.

5. Any major surgical procedure within one month of study entry.

6. Known serious allergies to fluorescein dye.

7. Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, Protein Kinase C inhibitors, etc) within last 6 months.

8. Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection or device implantation) in the study eye within the last 6 months.

9. History of subfoveal laser treatment in the study eye.

10. History of other visually-limiting conditions such as optic neuropathy, amblyopia, choroidal neovascularization due to causes other than IPT in the study eye.

11. Ocular inflammation (including trace or above) in the study eye.

12. Inability to comply with study or follow up procedures.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Ranibizumab
0.3 mg/0.05 ml dose
Ranibizumab
0.5 mg/0.05 ml dose

Locations

Country Name City State
United States The Wilmer Eye Institute at Johns Hopkins Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects with improvement of 15 or more letters of best corrected visual acuity from baseline to 3 months on an Early Treatment Diabetic Retinopathy visual acuity chart measured at 4 meters 3 months No
Secondary Retinal changes on ophthalmoscopy 3 months No
Secondary Retinal thickness measured by Optical Coherence Topography (OCT) 3 months No
Secondary Fluorescein leakage on fluorescein angiography 3 months No
Secondary Complications related to drug or its administration 12 months after last injection Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Terminated NCT04336163 - Skin Imaging to Inform Laser Treatments N/A
Completed NCT02286804 - Ultherapy for the Treatment of Spider Veins on the Legs N/A
Completed NCT03472859 - Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser N/A
Completed NCT01491620 - Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte N/A
Recruiting NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Completed NCT04148950 - Effects of Kinesio Taping Method on Functional Capacity and Quality of Life in Patients With Chronic Venous Disease N/A
Completed NCT00457067 - Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation Phase 1
Completed NCT00457145 - Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation Phase 1
Completed NCT04795310 - Clinical Observation of Pulsed Dye Laser and Intense Pulsed Light in Treating Facial Telangiectasia N/A
Completed NCT04274842 - D-OCT of Facial Telangiectasia Treated With IPL N/A
Recruiting NCT05978986 - Efficiency of Determining the Clinical Class of Chronic Venous Disorders by Artificial Intelligence N/A
Completed NCT05036200 - Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma N/A